These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29133566)

  • 1. Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens.
    Lodise TP; Bosso J; Kelly C; Williams PJ; Lane JR; Huang DB
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
    Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infections.
    Huang DB; Charrier C; Le Bras C; Hawser S; Noviello S
    J Med Microbiol; 2019 Jun; 68(6):898-902. PubMed ID: 31050628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
    Huang DB; Corey GR; Holland TL; Lodise T; O'Riordan W; Wilcox MH; File TM; Dryden M; Balser B; Desplats E; Torres A
    Int J Antimicrob Agents; 2018 Aug; 52(2):233-240. PubMed ID: 29783024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis.
    Fernández de Gatta Mdel M; Santos Buelga D; Sánchez Navarro A; Dominguez-Gil A; García MJ
    Clin Pharmacokinet; 2009; 48(4):273-80. PubMed ID: 19492872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1.
    Huang DB; O'Riordan W; Overcash JS; Heller B; Amin F; File TM; Wilcox MH; Torres A; Dryden M; Holland TL; McLeroth P; Shukla R; Corey GR
    Clin Infect Dis; 2018 Apr; 66(8):1222-1229. PubMed ID: 29281036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.
    Bhavnani SM; Hammel JP; Van Wart SA; Rubino CM; Reynolds DK; Forrest A; Drusano GL; Khariton T; Friedland HD; Riccobene TA; Ambrose PG
    Antimicrob Agents Chemother; 2015 Jan; 59(1):372-80. PubMed ID: 25367904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections.
    Krievins D; Brandt R; Hawser S; Hadvary P; Islam K
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2834-40. PubMed ID: 19414572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.
    Revilla N; Martín-Suárez A; Pérez MP; González FM; Fernández de Gatta Mdel M
    Br J Clin Pharmacol; 2010 Aug; 70(2):201-12. PubMed ID: 20653673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3935-41. PubMed ID: 14638504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-Resistant
    Song X; Han M
    Front Cell Infect Microbiol; 2022; 12():874401. PubMed ID: 35873144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Doripenem in Pediatric Patients and Monte-Carlo Pharmacokinetic-Pharmacodynamic Simulations for Dosing Regimen Assessment.
    Matsuo Y; Ishibashi T; Matsumoto S; Katsube T; Wajima T
    J Pharm Sci; 2019 Sep; 108(9):3099-3105. PubMed ID: 30974120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe.
    Huang DB; Magnet S; De Angelis S; Holland TL; File TM; Dryden M; Corey GR; Torres A; Wilcox MH
    Diagn Microbiol Infect Dis; 2019 Feb; 93(2):154-158. PubMed ID: 30266399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
    Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction.
    Ambrose PG; Bhavnani SM; Cirincione BB; Piedmonte M; Grasela TH
    J Antimicrob Chemother; 2003 Sep; 52(3):435-40. PubMed ID: 12917247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.
    Morgan A; Cofer C; Stevens DL
    Future Microbiol; 2009 Mar; 4(2):131-44. PubMed ID: 19257839
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Noviello S; Magnet S; Hawser S; Huang DB
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30642922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.